| pubmed-article:9610709 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9610709 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9610709 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:9610709 | lifeskim:mentions | umls-concept:C1512162 | lld:lifeskim |
| pubmed-article:9610709 | lifeskim:mentions | umls-concept:C0684224 | lld:lifeskim |
| pubmed-article:9610709 | lifeskim:mentions | umls-concept:C0007137 | lld:lifeskim |
| pubmed-article:9610709 | lifeskim:mentions | umls-concept:C0460004 | lld:lifeskim |
| pubmed-article:9610709 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:9610709 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:9610709 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:9610709 | lifeskim:mentions | umls-concept:C0205088 | lld:lifeskim |
| pubmed-article:9610709 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:9610709 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:9610709 | pubmed:dateCreated | 1998-6-11 | lld:pubmed |
| pubmed-article:9610709 | pubmed:abstractText | A number of single agents have been tested in patients with carcinoma of the head and neck receiving palliative treatment. In general, 15-30% of patients achieve a partial response lasting 3-4 months. Treatment has not been shown to alter survival rates. It is clear that new drugs with potentially greater activity need to be identified. For this purpose, the Eastern Cooperative Oncology Group conducted a Phase II evaluation of paclitaxel. | lld:pubmed |
| pubmed-article:9610709 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9610709 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9610709 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9610709 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9610709 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9610709 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9610709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9610709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9610709 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9610709 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:9610709 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:9610709 | pubmed:author | pubmed-author:TaylorS... | lld:pubmed |
| pubmed-article:9610709 | pubmed:author | pubmed-author:AdamsGG | lld:pubmed |
| pubmed-article:9610709 | pubmed:author | pubmed-author:ShaneNN | lld:pubmed |
| pubmed-article:9610709 | pubmed:author | pubmed-author:DeContiR CRC | lld:pubmed |
| pubmed-article:9610709 | pubmed:author | pubmed-author:NeubergDD | lld:pubmed |
| pubmed-article:9610709 | pubmed:author | pubmed-author:ForastiereA... | lld:pubmed |
| pubmed-article:9610709 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9610709 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:9610709 | pubmed:volume | 82 | lld:pubmed |
| pubmed-article:9610709 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9610709 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9610709 | pubmed:pagination | 2270-4 | lld:pubmed |
| pubmed-article:9610709 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:9610709 | pubmed:meshHeading | pubmed-meshheading:9610709-... | lld:pubmed |
| pubmed-article:9610709 | pubmed:meshHeading | pubmed-meshheading:9610709-... | lld:pubmed |
| pubmed-article:9610709 | pubmed:meshHeading | pubmed-meshheading:9610709-... | lld:pubmed |
| pubmed-article:9610709 | pubmed:meshHeading | pubmed-meshheading:9610709-... | lld:pubmed |
| pubmed-article:9610709 | pubmed:meshHeading | pubmed-meshheading:9610709-... | lld:pubmed |
| pubmed-article:9610709 | pubmed:meshHeading | pubmed-meshheading:9610709-... | lld:pubmed |
| pubmed-article:9610709 | pubmed:meshHeading | pubmed-meshheading:9610709-... | lld:pubmed |
| pubmed-article:9610709 | pubmed:meshHeading | pubmed-meshheading:9610709-... | lld:pubmed |
| pubmed-article:9610709 | pubmed:meshHeading | pubmed-meshheading:9610709-... | lld:pubmed |
| pubmed-article:9610709 | pubmed:meshHeading | pubmed-meshheading:9610709-... | lld:pubmed |
| pubmed-article:9610709 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9610709 | pubmed:articleTitle | Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). | lld:pubmed |
| pubmed-article:9610709 | pubmed:affiliation | Johns Hopkins Oncology Center, Baltimore, Maryland 21287-8936, USA. | lld:pubmed |
| pubmed-article:9610709 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9610709 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9610709 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9610709 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9610709 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9610709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9610709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9610709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9610709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9610709 | lld:pubmed |
